--- a
+++ b/clusters/9knumclustersv2/clust_1307.txt
@@ -0,0 +1,34 @@
+Primary immunodeficiency disorder or other nonmalignant inherited disease (except Fanconi anemia) treatable by allogeneic HCT
+Fanconi anemia
+Inherited bone marrow failure syndromes. At minimum, the diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow.
+Patients with idiopathic aplastic anemia and Fanconi anemia; (patients with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria [PNH] or inherited marrow failure syndromes, except Fanconi anemia, will be allowed)
+Bone marrow failure syndromes, except for Fanconi anemia
+Patients with Fanconi anemia; at a minimum, the diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow in patients younger than  years of age; (additional mutational testing may have been performed in a clinical or research capacity on a per patient basis but is not considered an exclusion criteria)
+Acquired bone marrow failure syndromes, except for Fanconi anemia
+Fanconi Anemia or other underlying bone marrow failure syndrome
+Diagnosis of Fanconi anemia must be excluded by mitomycin C or diepoxybutane chromosomal breakage testing on peripheral blood at a CLIA-approved laboratory (not required for patients with a genetic mutation consistent with DC)
+Diagnosis of Fanconi anemia
+Patients with Fanconi anemia (FA) must have aplastic anemia (AA), myelodysplastic syndrome without excess blasts, or high risk genotype as defined below\r\n* Aplastic anemia is defined as having at least one of the following when not receiving growth factors or transfusions:\r\n** Platelet count <  x ^ IL\r\n** Absolute neutrophil count (ANC) <  x ^/L\r\n** Hemoglobin (Hgb) <  g/dL\r\n* Myelodysplastic syndrome with multilineage dysplasia with or without chromosomal anomalies\r\n* High risk genotype (e.g. IVS- or exon  FANCC mutations, or BRCA or  mutations)
+Bone marrow failure syndromes, except for Fanconi anemia
+Acquired bone marrow failure syndromes except for Fanconi anemia or dyskeratosis congenita
+Diamond Blackfan anemia;
+Fanconi anemia (FA)
+Patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other inherited bone marrow failure syndromes are not eligible
+Fanconi anemia
+Primary immunodeficiency disorder or other nonmalignant inherited disease (except aplastic anemia and Fanconi anemia) treatable by allogeneic HCT
+Patients with Aplastic anemia and Fanconi anemia
+Non-malignant disorders deemed curable by allogeneic transplantation: a. primary immune deficiencies, b. severe aplastic anemia not responding to immune suppressive therapy, c. osteopetrosis d. selected cases of erythroid disorders such as ? ? thalassemia major, sickle cell disease, Diamond-Blackfan anemia. e. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML). Note: Subjects will be eligible if they meet either item  OR item .
+Is undergoing transplant for the treatment of nonmalignant hematological disorders (for example: aplastic anemia, sickle cell anemia, thalassemias, Fanconi anemia).
+Fanconi Anemia
+Patients with Fanconi anemia or other cancer-predisposition syndromes
+Patients with history of Down's syndrome, Fanconi anemia or other known marrow failure condition
+Fanconi anemia (FA)
+Patients with Down syndrome and deoxyribonucleic acid (DNA) fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded
+Anemia below lower limit of normal or anemia requiring transfusion support as per center standard
+Anemia
+Diagnosis of Fanconi anemia must be excluded in patients younger than  years of age by diepoxybutane testing on peripheral blood or comparable testing on marrow.
+Other indications for HCT, including Fanconi anemia, other form of inherited bone marrow failure diseases, metabolic disorder, hemoglobinopathy, or immune deficiency
+Have hypothyroidism and anemia
+Patient with aplastic anemia will be excluded
+Persons with any other condition (such as lichen planus, Fanconi anemia, heavy tobacco use, etc) making them at higher risk for oral cancer development
+Subjects at increased risk for radiation toxicities, such as known collagen vascular disease (example, scleroderma, Sjogren's disease, etc) or other inherited radiation hypersensitivity syndromes (example, Gorlin syndrome, Fanconi anemia, ataxia-telangiectasia, etc.)